L&T Technology Services participates in IAA Mobility, Munich
L&T Technology Services (BSE: 540115, NSE: LTTS), a leading global digital engineering and R&D services company announced its participation in the elite IAA Mobility conference in Munich. LTTS will exhibit its cutting-edge offerings on Software Defined Vehicles and the future of Mobility, at Hall A3, Booth #24.
In its second edition the Internationale Automobil Ausstellung (IAA) in Munich (September 5 – 10) presents a transformative vision for the automotive industry, centered around sustainability, electrification, and innovative mobility solutions. As the automotive industry evolves, the IAA Mobility undoubtedly remains a crucial platform for shaping the future of mobility and fostering collaboration among key stakeholders. With leading international partner companies, 500+ delegates and speakers, it is considered as one of the world’s most progressive conferences for sustainability through electrification and digitalization.
The automobile and aviation industry holds the key to driving significant advancements in green mobility. Traditional Original Equipment Manufacturer’s (OEM) and new entrants are racing to make eco-friendly vehicles, and this competitive spirit will be the theme for this year’s summit.
Sustainability is at the forefront with exhibitors showcasing their commitment to eco-friendly practices, emphasizing the use of sustainable materials and the latest developments in smart mobility, and connected solutions. Innovations related to autonomous driving, vehicle-to-vehicle communication, and integrated mobility will be some of the solutions to be showcased. These advancements are aimed at revolutionizing urban transportation and individual mobility making it safer, more efficient, and environmentally friendly.
L&T Technology Services with its domain expertise in transportation and aerospace have been partnering with global automobile and aerospace OEMs over the last two decades. At IAA Mobility, it will demonstrate the myriad possibilities of Domain Controllers, Cloud Native Connected Development, Security, Virtualization, AI enabled features and functionality that will enable the Vehicle-to-Everything (V2X) communication along with Digital cockpit demo.
Working with ER&D partners has become key to address the challenges of vehicle electrification across the value chain while delving into the parameters in the EV ecosystem. Using multiple vendors for various stages of product development can increase complexity and costs. A partner like LTTS could help drive co-innovation by overcoming technology constraints while applying cross-industry learnings. The need for software-driven solutions in the electric mobility industry has compelled stakeholders to pursue high-performance computing platforms. ER&D services partners can provide computing models that consume less energy, boost performance, and optimize data-led algorithms. Additionally, they can deliver scalable software stacks that leverage sensors and physical components to provide the safety and performance that electric vehicles need. They utilize software to optimize focus areas such as third-party integration, feature deployment, CloudOps, and over-the-air updates. In addition, the rising complexity in technology embedded within electric vehicles demands software-defined designs, can overcome multi-layered challenges from software development to deployment and maintenance.
“The IAA Mobility summit provides an excellent platform for exchanging innovative ideas and sparking a more inclusive, sustainable future for tomorrow. This year’s participation will further our conviction to engineer leading solutions that enable Vehicle-to-Everything (V2X) communication, Digital cockpit demo, and AI-enabled features while prioritizing safety and security. We are committed to helping our clients address the challenges of vehicle electrification across the value chain, including domain controllers, cloud-native connected development, security, and virtualization. With our end-to-end security solutions, we ensure that our clients' products and services are protected from cyber threats and maintain regulatory compliance,” said Mr. Amit Chadha, CEO and Managing Director at L&T Technology Services.
The IAA Mobility summit convenes global mobility experts to present and discuss the latest trends and innovations. Workshops and panels on sustainability, digitalization, and the role of AI in the automotive industry foster knowledge sharing and collaboration among key stakeholders.
The LTTS Munich Center of Excellence (CoE)
L&T Technology Services has been expanding its presence in Germany, a crucial market for engineering and technology services. The Munich-based CoE, is focused on serving a leading German OEM. The center's Accredited Near Shore facility offers engineering and R&D expertise to the auto manufacturer's infotainment consoles and hybrid EVs. The proximity to the customer's campus allows L&T Technology Services to test a range of solutions on their product suite and provide real-time services.
Vehicle Electrification | eBook | L&T Technology Services (ltts.com)
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,300 employees spread across 22 global design centers, 28 global sales offices and 102 innovation labs as of June 30, 2023. For more information, please visit https://www.LTTS.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906702764/en/
Contact information
Aniruddha Basu
L&T Technology Services Limited
E: Aniruddha.Basu@Ltts.com
Anindita Sarkar
L&T Technology Services Limited
E: Anindita.Sarkar@Ltts.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom